Remdesivir
Opaganib plus standard of care for severe COVID-19 reduces mortality
Opaganib significantly reduced mortality and improved the time to recovery among patients hospitalized for severe COVID-19 who also received remdesivir and corticosteroids, according to a press release from the manufacturer.
FDA expands use of remdesivir in patients with COVID-19
The FDA recently announced it has expanded its approval of Gilead Sciences’ antiviral drug remdesivir — marketed in the U.S. as Veklury — to allow certain outpatients with COVID-19 to receive it.
Town Hall: What to Know About Omicron, Quarantines, Outpatient Management and More
In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic.
Early remdesivir for COVID-19 lowers hospitalization, death risk by 87%
An early 3-day course of remdesivir lowered the risk for hospitalization or death among nonhospitalized patients at high risk for severe COVID-19 by 87%, according to a study published in The New England Journal of Medicine.
Lenzilumab improves survival without ventilation in patients hospitalized with COVID-19
Lenzilumab significantly improved survival without the need for invasive mechanical ventilation among patients hospitalized with COVID-19, according to results of the LIVE-AIR trial published in The Lancet Respiratory Medicine.
Mortality on ECMO higher in second wave of patients with COVID-19
Mortality on extracorporeal membrane oxygenation was higher in the second wave of patients with COVID-19, despite improvements in treatment before ECMO initiation, according to data presented at the CHEST Annual Meeting.
Remdesivir reduces risk for COVID-19 hospitalization in high-risk patients
A 3-day course of IV remdesivir was safe, well tolerated and prevented COVID-19-related hospitalizations among high-risk COVID-19 patients, according to data presented at IDWeek.
'Cascade of Impact': COVID-19 surge again threatens patient access to maintenance drugs
In a disturbing repeat of last year’s run on hydroxychloroquine, U.S. health care systems are scrambling to maintain tocilizumab access for rheumatology patients following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases.
From 'success' to 'madness': Rheumatologists share their worldwide COVID-19 experiences
In a session here, attendees heard global perspectives from their rheumatology colleagues in Australia, Canada, Puerto Rico, the Caribbean, Brazil and India.
FDA OKs emergency use of baricitinib alone for COVID-19
The FDA has authorized emergency use of baricitinib alone for the treatment of adults and pediatric patients aged 2 years and older who are hospitalized with COVID-19.